The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0926 ET – GSK is likely to continue with plans to boost research and development spending next year after its strong third-quarter performance, UBS analysts write. The U.K. pharma group’s shingles drug Shingrix outperformed outside the U.S., offsetting weakness there that weighed on investor confidence in the treatment, the analysts said. Strong results for the respiratory syncytial virus treatment Arexvy indicate demand for it extending into the future, the analysts write. A delay in the launch of an HIV treatment to 2028 from 2027 was one blemish on otherwise solid results across GSK’s portfolio. Shares rise 4.3% to 17.14 pounds. (william.gray@wsj.com)

Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8